Filipine - engleză - FDA (Food And Drug Administration)

a-z market enterprises developers inc - sildenafil (as citrate) - tablet - 50mg

Filipine - engleză - FDA (Food And Drug Administration)

claris lifesciences phils inc - meropenem (as trihydrate) - powder for injection - 1 g

Filipine - engleză - FDA (Food And Drug Administration)

united labs inc - meropenem (as trihydrate) - powder for injection - 1 g

Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

apvma permit - hydroxyphenylbutanone acetate+acetic acid+ammonium acetate + others - unspecified class

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - aminolevulinic acid hydrochloride 10.2mg equivalent to aminolevulinic acid 8mg - dermal patch - 8 mg - active: aminolevulinic acid hydrochloride 10.2mg equivalent to aminolevulinic acid 8mg excipient: durotak 387-2353 scotchpak 1109 (baking film) pegoterate - treatment of mild to moderate actinic ketatoses (ak) lesions on the face and scalp.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hexaminolevulinate hydrochloride -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

galderma australia pty ltd - methyl aminolevulinate hydrochloride, quantity: 200 mg/g (equivalent: methyl aminolevulinate, qty 160 mg/g) - cream - excipient ingredients: self-emulsifying glyceryl monostearate; cetostearyl alcohol; peg-40 stearate; methyl hydroxybenzoate; propyl hydroxybenzoate; disodium edetate; glycerol; white soft paraffin; cholesterol; isopropyl myristate; arachis oil; almond oil; oleyl alcohol; purified water - treatment of thin or non-hyperkeratotic and non-pigmented actinic keratoses on the face and scalp when other registered therapies are unacceptable. primary treatment of superficial and/or nodular basal cell carcinoma where surgery is considered inappropriate. treatment of biopsy-proven squamous cell carcinoma in situ (bowen's disease), where surgery is considered inappropriate. lumexia is indicated in adults above 18 years of age.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - aminolevulinic acid hydrochloride, quantity: 10.2 mg (equivalent: aminolevulinic acid, qty 8 mg) - patch, dermal - excipient ingredients: polyethylene terephthalate; polyethylene; aluminium; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - treatment of mild to moderate actinic keratoses (ak) lesions on the face and scalp (hairless areas).

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

photocure inc - hexaminolevulinate hydrochloride (unii: d4f329sl1o) (hexaminolevulinate - unii:g7h20tki67) - hexaminolevulinate hydrochloride 100 mg in 50 ml - cysview is an optical imaging agent indicated for use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. cysview is used with the karl storz d-light c photodynamic diagnostic (pdd) system to perform cystoscopy with the blue light setting (mode 2) as an adjunct to the white light setting (mode 1). cysview is not: - a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer [see warnings and precautions (5.2) ]. - for repetitive use. the potential risks associated with repetitive exposure, including sensitization and adverse effects of blue light have not been evaluated [see warnings and precautions (5.1) ]. cysview is contraindicated in patients with: - porphyria - gross hematuria - bcg immunotherapy or intravesical chemotherapy within the past 90 days - known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid pregnancy

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sanofi pasteur inc. - yellow fever virus strain 17d-204 live antigen (unii: py4eet359t) (yellow fever virus strain 17d-204 live antigen - unii:py4eet359t) - yellow fever virus strain 17d-204 live antigen 4.74 [pfu] in 0.5 ml - yf-vax is indicated for active immunization for the prevention of yellow fever in persons 9 months of age and older in the following categories: while the actual risk for contracting yellow fever during travel is probably low, variability of itineraries, behaviors and seasonal incidence of disease make it difficult to predict the actual risk for a given individual living in or traveling to a known endemic or epidemic area. greater risk is associated with living in or traveling to areas of south america and africa where yellow fever infection is officially reported at the time of travel and with traveling outside the urban areas of countries that do not officially report the disease but that lie in a yellow fever endemic zone. some countries require an individual to have a valid international certificate of vaccination or prophylaxis (icvp) if the individual has been in countries either known or thought to harbor yellow fever virus. the certificate becomes valid 10 days after vaccination with yf-vax. (13) (14)